• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Meta-analysis of the efficacy and safety of Shenkang injection combined with Western medicine in the treatment of chronic glomerulonephritis

    2022-12-03 02:09:30YangLiuYueJiZiXuanZhaoLuXuanGuoJinLinRongXinZhengGuanRanWangJinHuaSiXinYuanZhangNaHaoHongTaoYang
    Clinical Research Communications 2022年4期
    關(guān)鍵詞:腎康慢性腎炎血尿

    Yang Liu ,Yue Ji ,Zi-Xuan Zhao ,Lu-Xuan Guo ,Jin Lin ,Rong-Xin Zheng ,Guan-Ran Wang,Jin-Hua Si,Xin-Yuan Zhang,Na Hao*,Hong-Tao Yang*

    1Nephrology Department,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300381,China.2National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Tianjin 300381,China.3School of Integrative Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China.4Psychosomatic Department,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300381,China.

    Abstract Objective:The purpose of the research was to systematically evaluate the clinical efficacy and safety of Shenkang injection combined with Western medicine in treating chronic glomerulonephritis.Methods:Randomized controlled trials of Shenkang Injection combined with Western medicine in treating CGN were obtained from 8 Science databases including China National Knowledge Infrastructure (CNKI),China Biomedical Database(SinMed),Weipu Database (VIP),Wanfang Database (Wanfang),PubMed,The Cochrane Library,Embase,Web of Science from establishment to June 2022.Two researchers screened literature and extracted useful data according to inclusion and exclusion criteria,and used RevMan 5.3 and STATA SE 14.0 software to perform meta-analysis.Results:1,214 patients were included in 15 studies,with 607 in treatment group and 607 in control group.The results of meta-analysis showed that the treatment group could improve the clinical effective rate[RR=1.33,95%CI(1.25,1.40),P<0.00001],reduce serum creatinine[MD=-31.28,95% CI (-42.90,-19.66), P<0.00001],blood urea nitrogen [MD=-2.26,95%CI(-3.08,-1.44), P<0.00001],24-hour urine protein quantification [MD=-0.37,95% CI(-0.49,-0.25), P<0.00001],tumor necrosis factor -α [MD=-7.93,95% CI(-10.56,-5.30),P<0.00001],systolic blood pressure[MD=-10.81,95%CI(-13.66,-7.96),P<0.00001]and diastolic blood pressure [MD=-7.36,95% CI (-9.34,-5.38), P<0.00001].Conclusion:Shenkang injection combined with Western medicine can enhance the clinical effective rate of CGN and reduce the levels of serum creatinine,blood urea nitrogen,24-hour urine protein quantification,tumor necrosis factor-α,systolic blood and diastolic blood pressure.However,due to the low quality of literature,the conclusion still needs to be supported by more multi-center,large-sample studies with rigorous design and standardized implementation.

    Keywords: Shenkang injection;chronic glomerulonephritis;curative effect;randomized controlled trials;meta-analysis

    Introduction

    Chronic glomerulonephritis (CGN),a representative chronic kidney disease (CKD),is characterized by haematuria,proteinuria,edema,and hypertension [1].In 2017,average prevalence of CKD was globally 9.1%,an increase of 29% compared with 1990 [2].CKD affects about 10% of adults worldwide,causing 1.2 million deaths per year [3].CKD,by 2040,is predicted to be the fifth leading cause of death worldwide [4].As renal function declines,patients will have different degrees of heart and lung function decline,malnutrition,psychological function and cognitive impairment,seriously affecting patients' quality of life [5,6].The studies have shown [7] that autoimmunity,infection and inflammation affect development of CGN,but specific pathogenesis and molecular mechanism of CGN remain unclear [8].Currently,antihypertensive,anticoagulant,hormonal and cytotoxic drugs are commonly used in treating CGN to alleviate severe symptoms and slow down the occurrence of renal failure.However,these treatment schemes also have disadvantages in efficacy,cost and side effects[9].More and more studies have verified the curative effect of Traditional Chinese medicine in the treatment of CGN [10,11].Shenkang injection (SKI) contains Dahuang (Rheum palmatum),Huangqi (Astragalus membranaceus),Danshen (Salvia miltiorrhiza) and Honghua (Carthamus tinctorius),which has the functions of relaxing bowel and lowering turbidity,it can invigorate qi and promote blood circulation,mainly applied in treating chronic renal failure [12-14].SKI can clear free radicals in the body,correct lipid metabolism disorder,delay the damage of renal function,inhibit protein decomposition,inhibit water and sodium retention,etc [15].SKI combined with Western medicine can significantly reduce the level of inflammatory factors such as interleukin-6 and tumor necrosis factor-α in patients,and improve the oxidative stress and inflammatory state of patients [16].Recent clinical observations have shown that SKI can significantly reduce the levels of serum creatinine,blood urea nitrogen and 24-hour urine protein quantification in CGN patients to improve clinical effective rate [17,18].At present,more and more clinical studies confirming positive effect of SKI on CGN patients have indicated clinical symptoms' improvement of CGN patients.However,there are differences in protocol design,evaluation criteria and observation indicators among different studies,and scientific evidence-based medicine methods are needed to evaluate its efficacy.Our study systematically gathered the randomized controlled trials (RCTs) of SKI combining Western medicine in treating CGN,so as to assist clinical practice in providing evidence.

    Methods

    This research was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and is registered in PROSPERO (CRD42022297770).

    Search strategy

    We gathered RCTs of SKI combining Western medicine in treating CGN from 8 Science databases including CNKI,VIP,Wanfang,SinoMed,PubMed,Embase,the Cochrane Library,and Web of Science from establishment to June 2022.Chinese search terms were as follows: 慢性腎炎,慢性腎小球腎炎,慢性原發(fā)性腎小球疾病,腎康注射液,腎康注射劑.English search terms were as follows: Shenkang injection,chronic nephritis,chronic glomerulonephritis,etc.Keywords combined with free words were used to search.Taking CNKI and PubMed as examples,their specific search strategies were as follows.The two researchers (Yang Liu and Yue Ji) extracted data from the included literature at the same time,including the authors,publication year,patient age,intervention measures,control measures,outcome indicators,course of disease and course of treatment.We used Excel spreadsheet tools to carefully record and check each other,and the third researcher (Na Hao) would help solve any differences.

    Inclusion and exclusion criteria

    Inclusion criteria.(1) Study types: RCTs of SKI combined with Western medicine in the treatment of CGN.(2) Study subjects:clinically diagnosed CGN patients presented with hematuria,proteinuria,edema,and hypertension.Regardless of race,sex,age and nationality,the intra-group basis linearity was good.Diagnosis basis:Guidelines for the diagnosis and treatment of chronic glomerulonephritis[19],Internal Medicine[20],Diagnosis,Syndrome differentiation and curative effect evaluation of Chronic glomerulonephritis (trial program)[21],Nephrology[22].(3) Interventions: The control group: either treatment of alprostadil injection,ACEI or ARB (no limits on drug dosage,daily use frequency,manufacturer,etc.).The treatment group was additionally given SKI (no limits on drug dose,daily drip frequency,manufacturer,etc.),and other treatments were the same as the control group.(4) Outcome indicators: Main outcome indicators:Clinical effective rate (referring toGuiding Principles for Clinical Research of New Chinese Medicine[23],Diagnosis,Syndrome differentiation and curative effect evaluation of Chronic glomerulonephritis(trial program)[24] andSummary of discussion on diagnosis and treatment of renal disease and efficacy criteria[25]),clinical efficacy rate=The number of significant and effective cases/total number of cases× 100%.Secondary outcome indicators: serum creatinine(Scr),blood urea nitrogen (BUN),24-hour urine protein quantification(24h-UP),tumor necrosis factor-α (TNF-α),systolic blood pressure(SBP)and diastolic blood pressure(DBP).Clinical studies must include one or more of these outcomes.

    Exclusion criteria.(1) Studies did not meet the correct diagnostic criteria;(2) Studies using SKI combined with other traditional Chinese medicine therapies;(3) Studies that only have abstracts and the original data cannot be fully obtained;(4)Duplicate published studies;(5) review,cases of famous doctors,case reports,animal experiments and other non-clinical RCT studies.

    Study selection and data extraction

    Two evaluators (Yang Liu and Yue Ji) independently screened the literature according to the inclusion and exclusion criteria,excluded obviously irrelevant literature and cross-checked the results.In case of any disagreement,a third party (Hong-Tao Yang) participated in the discussion and decided.The software of NoteExpress was used to delete duplicate literature,and further exclude non RCTs studies such as reviews,case reports and animal experiments by reading the title and abstract of the literature.Finally,we read the full text of the literature,reasonably screen the literature according to the inclusion and exclusion criteria,and determine the final included literature.

    Risk of bias analyses

    Two evaluators(Yang Liu and Yue Ji)assessed the literature quality of the incorporated research according to the Cochrane manual 5.1[26],including the generation of random sequences,allocation concealment,blind measures,the integrity of outcome indicators,selective reports,and other biases.

    Application of statistical methods

    Revman 5.3 software was used for analysis.The relative risk(RR) and mean difference (MD) were used as efficacy indicators for counting data and continuity variables.If the numerical units were inconsistent,the standardized mean difference (SMD) was used for analysis.The Chi-square test was used to test the heterogeneity of results.IfP>0.10,I2<50%,it was considered that the heterogeneity among studies was small,and the fixed effect model was used.IfP≤0.10,I2≥50%,it was considered that there was great heterogeneity among studies,and the random effect model was used,and the source of heterogeneity should be further evaluated through subgroup analysis or sensitivity analysis.We Used the random effect model after excluding significant clinical and methodological heterogeneity [27].STATA SE 14.0 software was used for sensitivity analysis to explore whether a single study impacted on the total effect size of outcome indicators.The funnel plot was used to detect publication bias (n>10) for the major outcome indicators,and publication bias was quantitatively detected by Begg's test and Egger's Test[28,29].IfP<0.05,publication bias was indicated in the outcome indicators,and publication bias was corrected by trim and fill method[30,31].

    Results

    Study characteristics

    According to the established retrieval formula,116 pieces of related literature were retrieved,55 duplicate literature were removed.Read the title and abstract further and exclude 10 articles that do not meet the inclusion exclusion criteria.Through reading the full text,36 studies that did not meet the inclusion and exclusion criteria were excluded.Finally,15 studies [17,18,32-44] were included,all of which were Chinese literature with publication years from 2017 to 2021 (Figure 1).

    The key features included in the studies are shown in Table 1.15 RCTs were included,including 1,214 patients,607 in the treatment group and 607 in the control group.Sample sizes for individual studies ranged from 54 to 120 people,and the therapy course was 12 to 120 days.The treatment group was treated with Shenkang injection combined with Western medicine,and the control group was treated with Western medicine.(Tables 1 and 2).

    Table 1 Included studies'characteristics.

    Bias's risk analyses

    We used the Cochrane Bias risk Assessment tool to assess bias's risk in the 15 RCTs.In terms of random sequence generation,9 literature[17,18,32,34,37,38,40,43,44] were grouped by random number table method and evaluated as "low risk".6 literature [33,35,36,39,41,42] neglected the randomization method and got an "unclear".In terms of allocation concealment and blinding,only one literature[35]proposed the "double-blind" scheme,which was evaluated as "low risk",and the rest neglected allocation concealment and blinding implementation,which were evaluated as "unclear".In terms of outcome data integrity,all the included studies had good integrity with no case loss.In terms of selective reporting,none of the included studies were published selectively.Other biases were not mentioned in any of the included literature (Figure 2).

    Meta-analysis results

    Clinical effective rate.14 studies [17,18,32-35,37-44] reported clinical effective rate,1,160 patients were enrolled,with 580 in treatment group and 580 in control group.The results showed that there was low heterogeneity among studies (P=0.10,I2=35%),so we used the fixed effect model for the meta-analysis.The results indicated significantly higher clinical effective rate of the treatment group than the control group with statistically significant difference[RR=1.33,95% CI(1.25,1.40),P<0.00001) (Figure 3).

    Figure 1 Literature retrieval and screening process

    Serum creatinine.10 studies[17,18,32-35,37,40,43,44]reported levels of Scr before and after treatment,including a total of 834 patients,with 417 in the treatment group and 417 in the control group.The adopt random effect model was used due to the large heterogeneity among studies [P<0.00001,I2=97%].The results showed that the treatment group had more advantages in reducing the level of Scr [MD=-31.28,95% CI (-42.90,-19.66),P<0.00001].It was proved that SKI combining western medicine had more advantages in reducing the level of Scr than conventional western medicine alone (Figure 4).

    We explored the source of heterogeneity through subgroup analysis.The results showed that the heterogeneity mainly came from the difference of treatment measures in the itreatment group.Conduct subgroup analysis basing different western drugs combined in the treatment group,which were divided into SKI+Alprostadil injection[18,33,35,40],SKI+Valsartan Tablets [17,34,44] and SKI +Benazepril Tablets [32,37,43].The results of heterogeneity test showed that the heterogeneity between SKI+Alprostadil injection was significantly reduced [P=0.06,I2=60%],no heterogeneity between SKI+Valsartan Tablets was seen [P=0.40,I2=0%],and the heterogeneity between SKI+Benazepril Tablets was still very high[P< 0.00001,I2=94%].The random effect model analysis indicated: SKI+Alprostadil injection [MD=-43.07,95% CI (-49.36,-36.78),P<0.00001],SKI+Valsartan Tablets[MD=-6.97,95%CI(-9.75,-4.18),P<0.00001],SKI+Benazepril Tablets[MD=-40.53,95% CI(-54.38,-26.68),P<0.00001].The subgroup analysis results confirmed statistically significant difference between treatment and control groups (P<0.05) (Figure 5).

    Blood urea nitrogen.10 studies [17,18,32-35,37,40,43,44]reported changes in the level of BUN before and after treatment,involving a total of 834 patients,with 417 in treatment group and 417 in control group.We used the random effect model for analysis due to significant heterogeneity among studies [P<0.00001,I2=95%].The results of meta-analysis showed that combined SKI had more obvious advantages in reducing the level of BUN on thr basis of Western medicine alone [MD=-2.26,95% CI (-3.08,-1.44),P<0.00001] (Figure 6).

    We analyzed the treatment group combined with different kinds of Western medicine to identify the source of heterogeneity.The heterogeneity test results indicated: there was no heterogeneity of SKI+Alprostadil injection [18,33,35,40] [P=0.45,I2=0%],the heterogeneity of SKI+Valsartan Tablets [17,34,44] was also significantly reduced [P=0.08,I2=60%],there was no heterogeneity among SKI+Benazepril Tablets [32,37,43] [P=0.94,I2=0%],the adopt random effect model for analysis:SKI+Alprostadil injection [MD=-2.11,95% CI (-2.38,-1.83),P<0.00001],SKI+Valsartan Tablets [MD=-0.66,95% CI (-1.09,-0.22),P=0.003],SKI+Benazepril Tablets [MD=-4.17,95% CI(-4.61,-3.72),P<0.00001].It shows that there were significant differences between the treatment group and the control group in reducing the level of BUN (P<0.05) (Figure 7).

    24-hour urine protein quantification.11 studies[17,18,32-34,36,37,41-44] reported the changes of the level of 24h-UP before and after SKI combining Western medicine in treating CGN,involving 878 patients,with 439 in treatment group and 439 in control group.The significant heterogeneity among the studies was still high after subgroup analysis based on different interventions and treatment courses in the treatment group.After eliminating individual studies one by one,the heterogeneity within the group has scarcely altered,and the confidence intervals are located on the left side of the invalid line of the forest map,demonstrating that the heterogeneity between studies has no impact on the results,so we adopted the random effect model,which showed that the treatment group was more advantageous in reducing the level of 24h-UP [MD=-0.37,95% CI(-0.49,-0.25),P<0.00001] (Figure 8).

    Tumor necrosis factor-α.3 studies [38,40,44] reported inter-group the level of TNF-α,including 282 patients totally,with 141 in treatment group and 141 in control group.We used the random effect model due to significant heterogeneity between studies [P=0.08,I2=60%].The meta-analysis results showed that combined SKI had more obvious advantages in reducing the level of TNF-α on the basis of western medicine alone [MD=-7.93,95% CI (-10.56,-5.30),P<0.00001].We observed significant reduction of heterogeneity after excluding Rui Liu [40] [P=0.31,I2=3%].Considering that the heterogeneity might be caused by various interventions and treatment courses,we adopted the fixed effect model,which presented statistically significant reduction in TNF-α between treatment and control group [MD=-6.81,95% CI (-8.49,-5.12),P<0.00001](Figure 9).

    Blood pressure.2 studies [32,43] reported the changes of SBP and DBP between groups,with 97 cases in the treatment group and 97 cases in the control group.The intra group heterogeneity of the two outcome indicators was low [P=1.00,I2=0%].The results of meta-analysis showed that the treatment group was significantly better than the control group in reducing the levels of SBP and DBP[MDSBP=-10.81,95%CI(-13.66,-7.96),P<0.00001],[MDDBP=-7.36,95% CI(-9.34,-5.38),P<0.00001] (Figures 10 and 11).

    Adverse reactions rate.3 studies [18,32,34] reported the occurrence of adverse reactions,involving 266 patients totally,with 133 in treatment group and 133 in control group.The results showed that there was low heterogeneity among studies [P=0.46,I2=0%].We used the fixed effect model due to low heterogeneity between studies [RR=0.46,95% CI (0.18,1.18),P=0.11)],and significant difference was not seen in adverse reactions incidence between treatment group and control group (P>0.05) (Figure 12).

    Sensitive analysis

    We used STATA SE 14.0 software to conduct sensitivity analysis on clinical effective rate,Scr,BUN and 24h-UP respectively to test results'stability,and the results were shown below.The combined effect size was still within 95% CI of the total effect size after removing one by one,indicating that the results were stable and reliable(Supplementary Figure S1-S4).

    Publication bias evaluation of clinical effective rate

    Qualitative detection of funnel plot.The software STATA SE14.0 was used to draw funnel plot for publication bias analysis of clinical effective rate,with effect size(logrr) as the horizontal coordinate and standard error of effect size (selogrr) as the vertical coordinate.Results showed that most of the scattered points were evenly distributed within the 95% confidence interval,and only a few scattered points were distributed outside the interval.The funnel plot showed obvious asymmetry,informing possibility of publication bias risk(Figure 13).

    Quantitative detection of Begg map and Egger's map.In order to clarify whether there was publication bias in clinical effective rate,Begg rank correlation test and Egger 's linear regression method were used for quantitative detection.Begg'test results showed that the Pr >|z|=0.001<0.05,Egger's test results showed that theP>|t|=0.000 <0.05,indicating significant publication bias in clinical effective rate results.Metatrim module in STATA SE 14.0 was used to identify and correct the publication bias of clinical effective rate,and the results were shown as: before using the trim and filling method,fixed effect model [RR=0.240,95% CI (0.186,0.294),P=0.000];random effect model [RR=0.254,95% CI (0.189,0.320),P=0.000].After 6 iterations of Linear method,6 studies were found to be missing.After including the missing studies,results were: after using the trim and filling method,fixed effect model [RR=0.184,95% CI(0.136,0.232),P=0.000];random effect model [RR=0.188,95%CI (0.133,0.263),P=0.000].The statistically significant 95% CI (P<0.05) of the fixed and the random effect model before and after using the trim and filling method indicated relatively robust clinical effective rate meta-analysis results,and the potential publication bias had little influence on it (Supplementary Figure S5-S7).

    Figure 2 Bias's risk summary

    Figure 3 Forest map of clinical effective rate meta-analysis

    Figure 4 Forest map of Scr meta-analysis

    Figure 5 Forest map of Scr subgroup meta-analysis of treatment group combining different Western drugs

    Figure 6 Forest map of BUN meta-analysis

    Figure 7 Forest map of BUN subgroup meta-analysis of treatment group combined with different Western drugs

    Figure 8 Forest map of 24h-UP meta-analysis

    Figure 9 Forest map of TNF-α meta-analysis

    Figure 10 Forest map of SBP meta-analysis

    Figure 11 Forest map of DBP meta-analysis

    Figure 12 Meta-analysis of adverse reactions incidence

    Figure 13 Funnel plot of clinical effective rate

    Discussion

    In Traditional Chinese Medicine,CGN belongs to the categories of"hematuria (血尿)","low back pain (腰痛)","edema (水腫)" and"fatigue (虛勞)" [45,46],and the pathogenesis is mainly attributed to spleen and kidney deficiency and the invasion of evil Qi,leading to symptoms of hematuria,edema and lumbago [47].Clinically,strengthening spleen and kidney,invigorating qi and promoting blood circulation are the main treatment methods to strengthen vital Qi and remove pathogens [48].Dahuang is the sovereign drug in SKI and has the effect of relaxing bowel and lowering turbidity,can promote blood circulation and remove dampness;Huangqi,as the minister drug,has the function of ascending the clear and descending the turbid,tonifying Qi and dispersing blood stasis;Danshen and Honghua,as the assistant drug,can help the sovereign drug promote blood circulation to remove blood stasis.The whole is skilled at invigorating Qi and activating blood circulation,relaxing bowel and lowering turbidity[49,50].Modern pharmacological studies have found that Dahuang contains anthraquinone derivatives,polysaccharides and other chemical components,which can reduce angiotensin converting enzyme production,improve the high metabolic status of residual kidney,increase glomerular filtration rate,reduce glomerular sclerosis and inhibit inflammation [51,52];Huangqi can reduce interleukin-6 and TNF-α [53,54] to regulate immune function and exert anti-inflammatory effect;Safflower yellow pigment,the main component of Honghua [55] can inhibit platelet aggregation and activation and prevent blood coagulation;Salvianolate [56],the main active component of Danshen can delay kidney injury by regulating transforming growth factor β1 (TGF-β1) and Monocyte Chemoattractant Protein 1 (MCP-1),and its water-soluble component[57]can inhibit or reduce lipid peroxidation by scavenging superoxide anions and hydroxyl radicals.In conclusion,SKI can be anti-inflammatory and anticoagulant,reduce platelet aggregation,promote the repair of kidney tissue,protect residual renal function,reduce the risk of transformation from CGN to chronic renal failure,and reduce the occurrence of various complications.

    In this study,the meta-analysis was conducted on 15 RCTs,and the results indicated better clinical effective rate of SKI combing conventional Western medicine than Western medicine alone.Combining SKI with modern medicine can better reduce the levels of Scr,BUN,24h-UP,TNF-α and BP.Due to the large heterogeneity after the combination of outcome indicators,considering the risk of bias caused by simple combination,subgroup analyses were conducted based on various Western medicine and different treatment course between groups,and the results all confirmed the effectiveness of SKI.In terms of adverse reactions,one case of nausea occurred in the treatment group of Ying Sun[34];Ping-Hua Li[32]reported 1 case of rash and 1 pruritus;Jin-Li Dong [18] reported 2 vascular pain and 1 local redness,and the three control groups also suffered adverse reactions of varying degrees.No statistical significance of adverse reaction incidence was seen between the treatment and the control group (P>0.05),indicating that SKI may not reduce adverse reactions occurrence.According to the retrospective analysis of 19 patients with SKI-induced adverse reaction by De-Long Duo [58],63.16%of the patients had adverse reactions after 30 min intravenous infusions,among which the top three adverse reactions were nervous system damage,skin and accessory damage,and systemic damage.Those adverse reactions may be due to the inclusion of polysaccharides,proteins and other complex macromolecular antigens,easy to produce allergic reactions [59].Some of the reasons may be due to irregular infusion and individual differences,such as unreasonable dosage and duration,drug mixing,and age differences[60].As for the safety of SKI,more clinical evidence is still needed to confirm it since we only included few literature.

    This study has some limitations: (1) the randomization of some studies was unclear,and few studies have used blinding and allocation hiding;(2) the included subjects were all from China,so there may be publication bias of specific population;(3) there were different diagnostic criteria in the diagnosis of CGN,and most of the literature did not explain the diagnostic criteria of CGN;(4) in the evaluation criteria of clinical effective rate,the accuracy of outcome indicators may be affected because the evaluation criteria have not been unified.

    Conclusion

    SKI combined with Modern medicine can improve the clinical effective rate of CGN and reduce the levels of Scr,BUN,24H-UP,TNF-α,SBP and DBP.However,due to the low quality of literature,the conclusion still needs to be supported by more multi-center,large-sample studies with rigorous design and standardized implementation.

    猜你喜歡
    腎康慢性腎炎血尿
    血尿的夢(mèng)魘 橫紋肌溶解
    中國自行車(2018年8期)2018-09-26 06:53:34
    出現(xiàn)血尿必須上醫(yī)院檢查
    人人健康(2016年21期)2016-11-05 11:05:31
    海昆腎喜膠囊聯(lián)合腎康注射液治療慢性腎衰42例療效觀察
    綜合護(hù)理在慢性腎炎合并抑郁患者中的應(yīng)用觀察
    六味地黃湯加減治療慢性腎炎蛋白尿258例
    蛋白尿方聯(lián)合科素亞治療慢性腎炎臨床分析
    34 例腎康注射液不良反應(yīng)報(bào)告
    腎康注射液聯(lián)合西醫(yī)治療慢性腎衰竭療效及對(duì)脂代謝紊亂的影響
    腎康注射液不良反應(yīng)特征分析
    尿TGF-β1檢測(cè)在診斷慢性腎炎中的臨床應(yīng)用
    欧美精品国产亚洲| 中文字幕人妻丝袜一区二区 | 午夜福利在线观看免费完整高清在| 日本午夜av视频| 中文字幕最新亚洲高清| 下体分泌物呈黄色| 国产精品.久久久| 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 国产极品粉嫩免费观看在线| 精品久久蜜臀av无| 男女高潮啪啪啪动态图| 日日摸夜夜添夜夜爱| 亚洲精品日本国产第一区| 日韩一区二区三区影片| 97在线人人人人妻| 国产又爽黄色视频| 久久这里有精品视频免费| kizo精华| 日本黄色日本黄色录像| 久久鲁丝午夜福利片| 日本黄色日本黄色录像| 成年人免费黄色播放视频| 久久久久国产网址| 看十八女毛片水多多多| 大陆偷拍与自拍| av.在线天堂| 交换朋友夫妻互换小说| 午夜日本视频在线| 69精品国产乱码久久久| 国产亚洲午夜精品一区二区久久| 狂野欧美激情性bbbbbb| 亚洲,欧美精品.| 天天躁夜夜躁狠狠久久av| 大片电影免费在线观看免费| 欧美精品亚洲一区二区| 亚洲国产精品999| 亚洲精品自拍成人| 国产精品女同一区二区软件| 国产在视频线精品| 久久国产亚洲av麻豆专区| 国产精品国产三级专区第一集| 2022亚洲国产成人精品| 免费高清在线观看视频在线观看| 国产精品偷伦视频观看了| 久久99蜜桃精品久久| 黄片无遮挡物在线观看| 国产熟女午夜一区二区三区| 少妇被粗大猛烈的视频| 国产国语露脸激情在线看| 各种免费的搞黄视频| 男女边吃奶边做爰视频| 久久精品久久精品一区二区三区| 麻豆精品久久久久久蜜桃| 亚洲视频免费观看视频| 午夜av观看不卡| 欧美日韩视频高清一区二区三区二| 建设人人有责人人尽责人人享有的| 国产不卡av网站在线观看| 亚洲一区二区三区欧美精品| 久久久久人妻精品一区果冻| 欧美亚洲日本最大视频资源| 欧美激情极品国产一区二区三区| 搡女人真爽免费视频火全软件| 高清不卡的av网站| av在线app专区| 99国产综合亚洲精品| 国产成人免费观看mmmm| 春色校园在线视频观看| 人妻 亚洲 视频| 日韩人妻精品一区2区三区| 国产精品欧美亚洲77777| 最近2019中文字幕mv第一页| 99re6热这里在线精品视频| 亚洲熟女精品中文字幕| 精品卡一卡二卡四卡免费| 久久精品国产鲁丝片午夜精品| 久久国产精品大桥未久av| 99久久中文字幕三级久久日本| 性色avwww在线观看| av在线老鸭窝| 日韩一本色道免费dvd| 男女高潮啪啪啪动态图| 久久久久久人人人人人| 99国产综合亚洲精品| 免费不卡的大黄色大毛片视频在线观看| 美国免费a级毛片| 国产一区有黄有色的免费视频| 成年美女黄网站色视频大全免费| 国产片内射在线| 日韩中文字幕欧美一区二区 | 纯流量卡能插随身wifi吗| 久久久久久久久久久免费av| 精品久久蜜臀av无| 丝袜脚勾引网站| 少妇的逼水好多| 亚洲av国产av综合av卡| 一二三四中文在线观看免费高清| 波多野结衣av一区二区av| 成人毛片60女人毛片免费| 看十八女毛片水多多多| 国产精品人妻久久久影院| 中文乱码字字幕精品一区二区三区| 人妻 亚洲 视频| 在线观看免费日韩欧美大片| 久久影院123| 亚洲精品在线美女| 大香蕉久久网| 亚洲综合色网址| 少妇 在线观看| 亚洲成av片中文字幕在线观看 | 少妇人妻精品综合一区二区| 日本黄色日本黄色录像| 中文字幕色久视频| 最近2019中文字幕mv第一页| 性高湖久久久久久久久免费观看| 午夜激情久久久久久久| 黄网站色视频无遮挡免费观看| 中文字幕人妻丝袜一区二区 | 亚洲国产最新在线播放| 久久婷婷青草| 国产精品无大码| 午夜福利视频精品| 一级爰片在线观看| 国产成人免费观看mmmm| 最近2019中文字幕mv第一页| videosex国产| 亚洲欧洲日产国产| 国产成人欧美| 欧美最新免费一区二区三区| 黑人猛操日本美女一级片| 在线观看www视频免费| 国产欧美亚洲国产| 日韩大片免费观看网站| 久久久久久免费高清国产稀缺| 成人免费观看视频高清| 亚洲欧洲日产国产| 自线自在国产av| 国产免费福利视频在线观看| 9色porny在线观看| 国产亚洲av片在线观看秒播厂| 满18在线观看网站| 啦啦啦在线免费观看视频4| 极品少妇高潮喷水抽搐| 亚洲精品久久久久久婷婷小说| 国产av国产精品国产| 久久久国产欧美日韩av| 成人手机av| 久久韩国三级中文字幕| 午夜免费观看性视频| 国产精品偷伦视频观看了| 男男h啪啪无遮挡| 一个人免费看片子| 亚洲天堂av无毛| 国产av国产精品国产| 午夜福利视频在线观看免费| 制服诱惑二区| 欧美国产精品va在线观看不卡| 精品人妻在线不人妻| 欧美精品一区二区免费开放| 性色avwww在线观看| 少妇被粗大的猛进出69影院| 精品久久久久久电影网| 少妇人妻精品综合一区二区| 国产精品av久久久久免费| 国产男女内射视频| 久久精品国产亚洲av天美| 日本-黄色视频高清免费观看| 伦理电影免费视频| 91成人精品电影| 日韩人妻精品一区2区三区| 久久青草综合色| 亚洲国产毛片av蜜桃av| 18在线观看网站| 高清不卡的av网站| 久久久欧美国产精品| 日韩伦理黄色片| 我要看黄色一级片免费的| 免费看不卡的av| 亚洲欧美成人综合另类久久久| 老司机亚洲免费影院| 久久亚洲国产成人精品v| 亚洲国产av影院在线观看| 下体分泌物呈黄色| 久久久国产精品麻豆| 亚洲内射少妇av| 如何舔出高潮| 一级,二级,三级黄色视频| 国产成人免费无遮挡视频| 国产成人精品一,二区| 国产精品偷伦视频观看了| 久久精品国产综合久久久| 日韩一区二区视频免费看| 国产熟女午夜一区二区三区| 超碰成人久久| 久久精品人人爽人人爽视色| 国产精品一区二区在线不卡| 亚洲精品一区蜜桃| 最新的欧美精品一区二区| 卡戴珊不雅视频在线播放| 精品一区二区三卡| 99热网站在线观看| 香蕉精品网在线| 满18在线观看网站| 久久午夜福利片| 赤兔流量卡办理| 精品国产一区二区久久| 天堂俺去俺来也www色官网| 国产有黄有色有爽视频| 中文字幕av电影在线播放| 久久国产精品男人的天堂亚洲| 青草久久国产| 日韩免费高清中文字幕av| 久久毛片免费看一区二区三区| 最新中文字幕久久久久| 欧美日韩av久久| 美女高潮到喷水免费观看| 久久久国产一区二区| 在线亚洲精品国产二区图片欧美| 精品福利永久在线观看| 春色校园在线视频观看| 久久精品人人爽人人爽视色| 久久久久久久精品精品| 精品一品国产午夜福利视频| 99久久中文字幕三级久久日本| 啦啦啦啦在线视频资源| 亚洲激情五月婷婷啪啪| www日本在线高清视频| 久久久久精品人妻al黑| 中国国产av一级| 波多野结衣av一区二区av| 日本av免费视频播放| 女性被躁到高潮视频| 国产欧美亚洲国产| 青青草视频在线视频观看| 巨乳人妻的诱惑在线观看| 亚洲天堂av无毛| 9热在线视频观看99| 成人免费观看视频高清| 国产视频首页在线观看| 亚洲第一av免费看| 日日撸夜夜添| 免费黄网站久久成人精品| 麻豆av在线久日| 欧美日韩国产mv在线观看视频| 久久av网站| 欧美精品国产亚洲| tube8黄色片| 制服诱惑二区| 建设人人有责人人尽责人人享有的| 久久人妻熟女aⅴ| 国精品久久久久久国模美| av视频免费观看在线观看| 亚洲av男天堂| 亚洲图色成人| 国产国语露脸激情在线看| 久久人人爽人人片av| 肉色欧美久久久久久久蜜桃| 91在线精品国自产拍蜜月| 久久婷婷青草| 欧美精品国产亚洲| 亚洲国产毛片av蜜桃av| 日韩不卡一区二区三区视频在线| 亚洲精品中文字幕在线视频| 国产精品 国内视频| 亚洲综合精品二区| 亚洲av电影在线进入| 国产综合精华液| 成年动漫av网址| 菩萨蛮人人尽说江南好唐韦庄| 亚洲精品在线美女| 超色免费av| 亚洲一区中文字幕在线| 亚洲成人av在线免费| 久久综合国产亚洲精品| 熟女av电影| 欧美日韩亚洲国产一区二区在线观看 | 午夜福利在线观看免费完整高清在| 日日爽夜夜爽网站| 久久精品国产亚洲av涩爱| 国产男女内射视频| 久久狼人影院| 久久久国产一区二区| 女人高潮潮喷娇喘18禁视频| xxxhd国产人妻xxx| 高清视频免费观看一区二区| 中国国产av一级| 久久婷婷青草| 免费久久久久久久精品成人欧美视频| 国产亚洲av片在线观看秒播厂| 看非洲黑人一级黄片| 日韩一区二区三区影片| 国产黄色免费在线视频| 最近的中文字幕免费完整| 午夜福利在线观看免费完整高清在| 美女福利国产在线| 国产一区二区激情短视频 | 丝袜美腿诱惑在线| 久久99热这里只频精品6学生| 免费看不卡的av| 午夜激情久久久久久久| videos熟女内射| 在线观看免费日韩欧美大片| 欧美成人午夜精品| 亚洲精品自拍成人| 少妇人妻精品综合一区二区| 日韩av在线免费看完整版不卡| 免费在线观看视频国产中文字幕亚洲 | 中国国产av一级| 午夜福利乱码中文字幕| 欧美中文综合在线视频| 日韩视频在线欧美| 亚洲国产欧美在线一区| 天天影视国产精品| 精品久久蜜臀av无| 国产免费又黄又爽又色| 成年女人毛片免费观看观看9 | 又黄又粗又硬又大视频| 肉色欧美久久久久久久蜜桃| 嫩草影院入口| 老司机影院毛片| 久久国产亚洲av麻豆专区| 精品少妇黑人巨大在线播放| 综合色丁香网| 捣出白浆h1v1| 日日摸夜夜添夜夜爱| 十八禁网站网址无遮挡| 午夜免费鲁丝| 免费大片黄手机在线观看| 黄片播放在线免费| 欧美激情 高清一区二区三区| 黑人猛操日本美女一级片| 精品视频人人做人人爽| 国产男女内射视频| 日韩视频在线欧美| 午夜久久久在线观看| 亚洲三级黄色毛片| 日韩av免费高清视频| 一个人免费看片子| 青草久久国产| 2021少妇久久久久久久久久久| 国产伦理片在线播放av一区| 汤姆久久久久久久影院中文字幕| 亚洲,一卡二卡三卡| 日韩视频在线欧美| 国产精品免费大片| 人妻 亚洲 视频| 午夜久久久在线观看| 男人添女人高潮全过程视频| 有码 亚洲区| 男人添女人高潮全过程视频| 国产成人午夜福利电影在线观看| 女人被躁到高潮嗷嗷叫费观| 亚洲人成网站在线观看播放| 久久久国产精品麻豆| 这个男人来自地球电影免费观看 | 国产精品欧美亚洲77777| 久久 成人 亚洲| 一级a爱视频在线免费观看| 午夜福利视频在线观看免费| 久久国产精品大桥未久av| 女人精品久久久久毛片| 午夜日韩欧美国产| 一级爰片在线观看| 男的添女的下面高潮视频| 亚洲国产精品一区三区| 亚洲精品中文字幕在线视频| a级片在线免费高清观看视频| 亚洲精品aⅴ在线观看| 日韩av免费高清视频| 欧美精品亚洲一区二区| 欧美老熟妇乱子伦牲交| 又大又黄又爽视频免费| 高清不卡的av网站| 精品99又大又爽又粗少妇毛片| 久久久精品区二区三区| 天天躁夜夜躁狠狠躁躁| 最近中文字幕2019免费版| 国产亚洲欧美精品永久| 国产乱来视频区| 人妻一区二区av| 国产精品成人在线| 国产人伦9x9x在线观看 | 久久精品国产亚洲av涩爱| 欧美日韩成人在线一区二区| 丰满乱子伦码专区| 777久久人妻少妇嫩草av网站| 成年女人在线观看亚洲视频| 午夜福利网站1000一区二区三区| 国产精品人妻久久久影院| 免费在线观看视频国产中文字幕亚洲 | 女人久久www免费人成看片| 美女主播在线视频| 日本爱情动作片www.在线观看| 999精品在线视频| 老汉色av国产亚洲站长工具| 欧美人与性动交α欧美精品济南到 | 成人国语在线视频| 欧美人与性动交α欧美软件| 免费黄频网站在线观看国产| 亚洲成人av在线免费| 精品一区二区免费观看| 国产免费一区二区三区四区乱码| 亚洲少妇的诱惑av| 黄频高清免费视频| 亚洲国产欧美在线一区| 久久久久国产精品人妻一区二区| 久久av网站| 国产精品一国产av| 午夜日韩欧美国产| 久热这里只有精品99| av免费观看日本| 热99国产精品久久久久久7| 欧美人与善性xxx| av免费在线看不卡| 最近2019中文字幕mv第一页| 黄色一级大片看看| 2018国产大陆天天弄谢| 国产精品久久久久久久久免| 日本-黄色视频高清免费观看| 国产精品欧美亚洲77777| 亚洲av综合色区一区| 老司机影院毛片| 国产精品一区二区在线不卡| 18禁动态无遮挡网站| 国产熟女欧美一区二区| 国产激情久久老熟女| 国产亚洲一区二区精品| 欧美最新免费一区二区三区| 欧美国产精品一级二级三级| 亚洲美女搞黄在线观看| 肉色欧美久久久久久久蜜桃| 多毛熟女@视频| 国产一级毛片在线| 大话2 男鬼变身卡| 日本爱情动作片www.在线观看| 国产色婷婷99| av免费观看日本| 超碰成人久久| 久久毛片免费看一区二区三区| 中文欧美无线码| 亚洲成人手机| 亚洲国产毛片av蜜桃av| 亚洲天堂av无毛| 国产 精品1| 在线天堂最新版资源| 两个人免费观看高清视频| 国产女主播在线喷水免费视频网站| 欧美国产精品一级二级三级| 婷婷成人精品国产| 色网站视频免费| 男女边吃奶边做爰视频| 成人二区视频| 大陆偷拍与自拍| 国产精品免费大片| 久久精品国产a三级三级三级| 亚洲av国产av综合av卡| 少妇猛男粗大的猛烈进出视频| 极品少妇高潮喷水抽搐| 男女啪啪激烈高潮av片| 国产成人免费无遮挡视频| 亚洲欧美一区二区三区久久| 日韩视频在线欧美| 久久精品国产自在天天线| 男人爽女人下面视频在线观看| 日韩,欧美,国产一区二区三区| 国产精品三级大全| videos熟女内射| 亚洲精品,欧美精品| 亚洲欧美一区二区三区久久| 日韩,欧美,国产一区二区三区| 熟女少妇亚洲综合色aaa.| 丝袜在线中文字幕| 亚洲一区二区三区欧美精品| 一级毛片我不卡| 国产一区二区三区综合在线观看| 97在线视频观看| 女人高潮潮喷娇喘18禁视频| 国产极品天堂在线| 欧美人与性动交α欧美软件| 亚洲国产精品999| 熟女少妇亚洲综合色aaa.| 中文字幕亚洲精品专区| 欧美精品一区二区大全| 91精品伊人久久大香线蕉| 18+在线观看网站| av又黄又爽大尺度在线免费看| 九九爱精品视频在线观看| 青草久久国产| 黄色视频在线播放观看不卡| 久久精品人人爽人人爽视色| 少妇的丰满在线观看| 国产乱来视频区| 一级毛片黄色毛片免费观看视频| 搡老乐熟女国产| 老女人水多毛片| 亚洲美女黄色视频免费看| 99久久精品国产国产毛片| 亚洲视频免费观看视频| 菩萨蛮人人尽说江南好唐韦庄| 少妇熟女欧美另类| 最近中文字幕2019免费版| 亚洲av电影在线观看一区二区三区| 日韩制服丝袜自拍偷拍| 2022亚洲国产成人精品| 精品久久久精品久久久| 国产成人一区二区在线| 自拍欧美九色日韩亚洲蝌蚪91| 美女视频免费永久观看网站| 成人毛片60女人毛片免费| 啦啦啦视频在线资源免费观看| 成年动漫av网址| 精品一区二区免费观看| 韩国高清视频一区二区三区| 午夜福利在线观看免费完整高清在| 精品少妇久久久久久888优播| 免费少妇av软件| 又大又黄又爽视频免费| 亚洲欧美日韩另类电影网站| 你懂的网址亚洲精品在线观看| 在线观看美女被高潮喷水网站| 一级爰片在线观看| 免费播放大片免费观看视频在线观看| 亚洲欧美日韩另类电影网站| 免费观看在线日韩| 亚洲精品久久午夜乱码| 两个人免费观看高清视频| 一级片'在线观看视频| videos熟女内射| 国产欧美日韩综合在线一区二区| 麻豆精品久久久久久蜜桃| 男的添女的下面高潮视频| 国产精品熟女久久久久浪| 成人亚洲欧美一区二区av| 久久久久久久精品精品| 亚洲精品一二三| av免费在线看不卡| 精品人妻一区二区三区麻豆| 精品国产一区二区久久| 免费黄网站久久成人精品| 99香蕉大伊视频| 亚洲精品中文字幕在线视频| 汤姆久久久久久久影院中文字幕| 超碰成人久久| 成人亚洲欧美一区二区av| 亚洲婷婷狠狠爱综合网| 久久久久久久久久久免费av| 国产成人免费无遮挡视频| 在线天堂中文资源库| 91在线精品国自产拍蜜月| 国产欧美亚洲国产| 观看美女的网站| 国产精品二区激情视频| 久久ye,这里只有精品| 成人午夜精彩视频在线观看| 亚洲内射少妇av| 80岁老熟妇乱子伦牲交| 国产亚洲欧美精品永久| 午夜影院在线不卡| 一级毛片 在线播放| av在线app专区| av片东京热男人的天堂| 亚洲少妇的诱惑av| 99久久中文字幕三级久久日本| 老女人水多毛片| 少妇的丰满在线观看| 国产成人精品一,二区| 最近最新中文字幕免费大全7| 国产乱人偷精品视频| 视频区图区小说| 在线亚洲精品国产二区图片欧美| 亚洲美女黄色视频免费看| 三级国产精品片| 91午夜精品亚洲一区二区三区| 国产精品嫩草影院av在线观看| 人体艺术视频欧美日本| 男男h啪啪无遮挡| 日韩,欧美,国产一区二区三区| 久久人人爽av亚洲精品天堂| 国产不卡av网站在线观看| 国产亚洲午夜精品一区二区久久| 国产色婷婷99| 亚洲综合色网址| 日韩视频在线欧美| xxx大片免费视频| 亚洲第一av免费看| 在线观看三级黄色| 国产一区有黄有色的免费视频| 亚洲综合色惰| av在线app专区| 国产成人免费观看mmmm| 亚洲国产精品国产精品| 国产一区二区在线观看av| 韩国精品一区二区三区| 国产麻豆69| videos熟女内射| 中文精品一卡2卡3卡4更新| 国产av一区二区精品久久| 夫妻午夜视频| 午夜福利乱码中文字幕| 欧美国产精品一级二级三级| 久热这里只有精品99| 一级毛片电影观看| av视频免费观看在线观看| 男女高潮啪啪啪动态图| 欧美激情 高清一区二区三区| 人人澡人人妻人| 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 欧美另类一区| 欧美激情 高清一区二区三区| 久久99热这里只频精品6学生| 看免费成人av毛片| 热re99久久国产66热| 日本免费在线观看一区| 国产老妇伦熟女老妇高清| 老鸭窝网址在线观看|